physIQ to deploy remote monitoring platform for COVID-19 care

Originally published in BioWorld

The U.S. FDA has OK’d expanded labeling for physIQ Inc.’s continuous remote monitoring system, pinpointIQ, for use during the COVID-19 pandemic. The machine learning-based platform, including Multivariate Change Index (MCI), will allow clinicians to track physiologic changes in homebound, quarantined or high-risk patients with confirmed or suspected COVID-19 – freeing up hospital beds for the most severe cases and reducing exposure of doctors and nurses to the highly contagious disease.